Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Australian medtech firm Orthocell hit a new U.S. sales milestone for its Remplir nerve wrap in October 2026, signaling growing market traction.
Australian medical device maker Orthocell Ltd recorded its strongest month of U.S. sales for its Remplir nerve wrap product since the device's commercial launch, according to a company announcement. The October 2026 result — 92 units sold — marks a milestone for the FDA-cleared product as it competes in the peripheral nerve repair segment.
Remplir is a collagen-based nerve wrap engineered to support the repair and protection of peripheral nerves following injury or surgical trauma. Designed and manufactured in Australia, the device has received U.S. Food and Drug Administration clearance and is positioning itself as a category leader in key international markets, the company said.
Read more MSIG USA Names Andrew Pateyuk Head of Retail and Wholesale Property →
The October performance underscores a broader commercial trajectory for Orthocell as it pushes deeper into the competitive U.S. medical device market. Peripheral nerve repair is a specialized surgical segment that encompasses both acute trauma cases and elective procedures, making sustained monthly sales growth a meaningful indicator of clinical adoption.
Analysts tracking the medtech sector have noted that FDA-cleared nerve repair products face a long adoption curve, as surgeons must be trained on proper application techniques before routine use. A record monthly sales figure, while still early-stage, can signal that Orthocell's U.S. sales force and clinical education efforts are beginning to yield results.
Continue reading at All Financial Services & Investing.
